Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced an underwritten public offering...
Voyager Therapeutics’ $100 Million Common Stock Offering
Celldex Therapeutics’ $230.5 Million Common Stock Offering
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
Immunovant’s US$450 Million Common Stock Financing
Latham & Watkins represent the underwriters Leerink Partners LLC; Piper Sandler & Co.; Guggenheim Securities, LLC; Wells Fargo Securities, LLC; LifeSci Capital LLC. Immunovant, Inc. (Nasdaq:...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
Arhaus’ Class A Common Stock Secondary Offering
Latham & Watkins advises on Arhaus’ secondary offering of class A common stock by selling stockholders. Arhaus, Inc. (Nasdaq: ARHS), a rapidly growing lifestyle brand and...
Savers Value Village’s $400 Million Initial Public Offering
Paul, Weiss represents Savers Value Village, and Latham & Watkins represents the underwriters in the offering. Savers Value Village, Inc. announced the pricing of its upsized...
Wong v. Arlo Technologies Inc. et al
Davis Polk represented the underwriters, Cooley represented Arlo and its officers and directors, and Wilson Sonsini represented Netgear. In the California state and federal court securities...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
Xponential Fitness’ $122.5 Million Secondary Offering of Class A Common Stock
Davis Polk is advising Xponential Fitness on the offering, and Latham & Watkins is advising the underwriters involved. Xponential Fitness, Inc. has announced the pricing of...
Structure Therapeutics’ $185.3 Million IPO
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...